IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v23y2022i3d10.1007_s10198-021-01341-w.html
   My bibliography  Save this article

Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests

Author

Listed:
  • Juan Llano

    (Fundación Gaspar Casal)

  • Jorge Mestre-Ferrandiz

    (University Carlos III)

  • Jaime Espin

    (Escuela Andaluza de Salud Pública/Andalusian School of Public Health)

  • Jordi Gol-Montserrat

    (Fundación Gaspar Casal)

  • Alicia Llano

    (Fundación Gaspar Casal)

  • Carlos Bringas

    (Fundación Gaspar Casal)

Abstract

No abstract is available for this item.

Suggested Citation

  • Juan Llano & Jorge Mestre-Ferrandiz & Jaime Espin & Jordi Gol-Montserrat & Alicia Llano & Carlos Bringas, 2022. "Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(3), pages 329-335, April.
    • Handle: RePEc:spr:eujhec:v:23:y:2022:i:3:d:10.1007_s10198-021-01341-w
    DOI: 10.1007/s10198-021-01341-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01341-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-021-01341-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Jaime Espin & Michael Schlander & Brian Godman & Pippa Anderson & Jorge Mestre-Ferrandiz & Isabelle Borget & Adam Hutchings & Steven Flostrand & Adam Parnaby & Claudio Jommi, 2018. "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 803-817, December.
    2. Jorge Mestre-Ferrandiz & Néboa Zozaya & Bleric Alcalá & Álvaro Hidalgo-Vega, 2018. "Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?," PharmacoEconomics, Springer, vol. 36(12), pages 1407-1420, December.
    3. Reed Beall & Randall Kuhn, 2012. "Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis," PLOS Medicine, Public Library of Science, vol. 9(1), pages 1-9, January.
    4. Panos Kanavos & Anna-Maria Fontrier & Jennifer Gill & Olina Efthymiadou, 2020. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 129-151, February.
    5. Adrian Towse, 2020. "How Should the World Pay for a COVID-19 Vaccine?," Monograph 002287, Office of Health Economics.
    6. Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis, 2021. "Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 217-229, March.
    7. Juan Llano, 2007. "Discussion point: should governments buy drug patents?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 173-177, June.
    8. Brendan Shaw & Jorge Mestre-Ferrandiz, 2020. "Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices," PharmacoEconomics, Springer, vol. 38(2), pages 125-134, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bond, Eric W. & Saggi, Kamal, 2014. "Compulsory licensing, price controls, and access to patented foreign products," Journal of Development Economics, Elsevier, vol. 109(C), pages 217-228.
    2. Ramani, Shyama V. & Urias, Eduardo, 2018. "When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil," Research Policy, Elsevier, vol. 47(8), pages 1538-1552.
    3. Cremer, Helmuth & Lozachmeur, Jean-Marie, 2022. "Coinsurance vs. co-payments: Reimbursement rules for a monopolistic medical product with competitive health insurers," Journal of Health Economics, Elsevier, vol. 84(C).
    4. Gandjour, Afschin, 2022. "Value-based pricing of a COVID-19 vaccine," The Quarterly Review of Economics and Finance, Elsevier, vol. 84(C), pages 1-8.
    5. Bond, Eric W. & Saggi, Kamal, 2020. "Patent protection in developing countries and global welfare: WTO obligations versus flexibilities," Journal of International Economics, Elsevier, vol. 122(C).
    6. Etienne Billette de Villemeur & Vianney Dequiedt & Bruno Versaevel, 2021. "Covid-19: Should intellectual property rights be challenged? [Covid-19 : doit-on remettre en question les droits de propriété intellectuelle?]," Post-Print hal-03212246, HAL.
    7. Eric W. Bond & Kamal Saggi, 2017. "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," American Economic Journal: Microeconomics, American Economic Association, vol. 9(1), pages 31-62, February.
    8. Paul Oldham & Stephen Hall & Oscar Forero, 2013. "Biological Diversity in the Patent System," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-16, November.
    9. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
    10. Ramani, Shyama V. & Urias, Eduardo, 2015. "Access to critical medicines: When are compulsory licenses effective in price negotiations?," Social Science & Medicine, Elsevier, vol. 135(C), pages 75-83.
    11. Bond, Eric W. & Samuelson, Larry, 2019. "Bargaining with private information and the option of a compulsory license," Games and Economic Behavior, Elsevier, vol. 114(C), pages 83-100.
    12. Baten, Joerg & Bianchi, Nicola & Moser, Petra, 2017. "Compulsory licensing and innovation – Historical evidence from German patents after WWI," Journal of Development Economics, Elsevier, vol. 126(C), pages 231-242.
    13. Kjellberg, Hans & Sjögren, Ebba & Krafve, Linus Johansson, 2023. "The functions of known to be inaccurate prices in markets: A cross-country comparison of pharmaceutical list pricing," Journal of Business Research, Elsevier, vol. 167(C).
    14. Riccaboni, Massimo & Swoboda, Torben & Van Dyck, Walter, 2022. "Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model," Health Policy, Elsevier, vol. 126(6), pages 534-540.
    15. Eduardo Urias & Shyama V. Ramani, 2020. "Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence," Journal of International Business Policy, Palgrave Macmillan, vol. 3(4), pages 367-384, December.
    16. Sweet, Cassandra Mehlig & Eterovic Maggio, Dalibor Sacha, 2015. "Do Stronger Intellectual Property Rights Increase Innovation?," World Development, Elsevier, vol. 66(C), pages 665-677.
    17. Eric W Bond & Kamal Saggi, 2017. "Price controls versus compulsory licensing: effects on patent-holders and consumers," Vanderbilt University Department of Economics Working Papers 17-00013, Vanderbilt University Department of Economics.
    18. So-Young Ha & Dong-Won Kang & Hye-In Jung & Eui-Kyung Lee & Mi-Hai Park, 2022. "Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies," IJERPH, MDPI, vol. 19(7), pages 1-10, March.
    19. Carlos M. Correa, 2016. "Intellectual Property: How Much Room is Left for Industrial Policy?," Journal of International Commerce, Economics and Policy (JICEP), World Scientific Publishing Co. Pte. Ltd., vol. 7(02), pages 1-22, June.
    20. Joosse, Iris R. & Tordrup, David & Glanville, Julie & Kotas, Eleanor & Mantel-Teeuwisse, Aukje K. & van den Ham, Hendrika A., 2023. "Evidence on the effectiveness of policies promoting price transparency - A systematic review," Health Policy, Elsevier, vol. 134(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:23:y:2022:i:3:d:10.1007_s10198-021-01341-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.